Text Size

Potential neuroprotective effects of an LSD1 inhibitor in retinal ganglion cells via p38 MAPK activity

Tsutsumi T., Iwao K., Hayashi H., Kirihara T., Kawaji T., Inoue T., Hino S., Nakao M., Tanihara H.


  • 2016
  • Investigative Ophthalmology and Visual Science
View publication
  • Therapeutic Area

    Glaucoma

  • Affiliations

    Department of Ophthalmology and Visual Science, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan; Department of Applied Biochemistry, School of Pharmacy Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan; Translational Science R&D Division, Santen Pharmaceutical Co. Ltd, Osaka, Japan; Department of Medical Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan

Related Publications

Ab-Externo MicroShunt versus Trabeculectomy in Primary Open-Angle Glaucoma: 2-year Results from a Randomized, Multicenter Study

Panarelli JF, Moster MR, Garcia-Feijoo J, Flowers BE, Baker ND, Barnebey HS, Grover DS, Khatana AK, Lee B, Nguyen T, Stiles MC, Sadruddin O, Khaw PT.


Omidenepag Isopropyl in Latanoprost Low/Non-Responders with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3, Non-Randomized, Two-Phase, Open-Label Study

Panarelli JF, Bowden EC, Tepedino ME, Odani-Kawabata N, Pei Z, McLaurin EB, Ropo A.


The Development of a SIBS Shunt to Treat Glaucoma

Pinchuk L.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022